Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell

NCT01956903 is registered in ClinicalTrials.gov with Grupo Espanol de trasplantes hematopoyeticos y terapia celular as lead sponsor.

NCT NCT01956903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01956903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell
Lead sponsor
Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2010
Completion date
September 30, 2013
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic graft-versus-host disease